Wave Life Sciences Ltd. filings document a clinical-stage biotechnology company developing RNA medicines through the PRISM platform and Nasdaq-listed $0 par value ordinary shares under WVE. Its 8-K reports furnish operating and financial results, Regulation FD corporate presentations and material-event disclosures tied to clinical programs, regulatory communications and pipeline updates for oligonucleotide candidates including WVE-006 and WVE-007.
Proxy and governance filings cover shareholder voting matters, board and governance disclosures, material agreements, capital-structure information and risk factors. The company's formal disclosures also address clinical and regulatory risks, collaboration-related matters, financial condition, and the corporate controls associated with an RNA-medicines development business.
Wave Life Sciences, Inc. director Mark Corrigan acquired 10,700 restricted stock units and an option covering 64,000 common shares on October 5, 2026, under the 2026 Non-Employee Director Compensation Policy. Both awards vest in full on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. The option has a $3.75 per-share exercise price and expires October 5, 2036. After the awards, his reported common-stock position was 39,515 shares and his option position covered 64,000 shares.
Wave Life Sciences, Inc. director Adrian Rawcliffe received a 10,700-share restricted stock unit award and an option award covering 64,000 shares on October 5, 2026. The option has a $3.75 per-share exercise price and expires October 5, 2036. Both awards vest as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
Wave Life Sciences, Inc. (WVE) director Heidi L. Wagner received 10,700 restricted stock units and an option covering 64,000 common shares on October 5, 2026. The option has a $3.75 per-share exercise price and expires October 5, 2036. Both awards vest in full on the earlier of the company’s 2027 annual meeting of stockholders or October 5, 2027. Her reported direct common-stock position following the RSU award was 55,630 shares.
Wave Life Sciences, Inc. director Christian O. Henry was granted a 10,700-share restricted stock unit award and a stock option covering 64,000 common shares on October 5, 2026. His reported direct common-stock holdings following the RSU award were 23,400 shares. Both awards vest as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
Wave Life Sciences director Heidi L. Wagner exercised options for 7,000 ordinary shares at an exercise price of $5.97 per share on August 11, 2026, and sold the resulting 7,000 shares of common stock at $6.01 per share. The derivative position reported from this option grant was reduced to 0 following the transaction. The company notes these fully vested option exercises and related sale were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
Wave Life Sciences, Inc. director Adrian Rawcliffe reported selling 12,700 shares of common stock on August 12, 2026, in an open-market transaction at a reported price of $5.29 per share (weighted average). The sales were effected under a Rule 10b5-1 trading plan adopted on March 6, 2026, and left him with 0 shares of directly held common stock reported in this filing.
Wave Life Sciences, Inc. director Ken Takanashi reported selling 3,864 shares of common stock on August 11, 2026 at a weighted-average price of $6.01 per share, in transactions ranging from $6.01 to $6.03. The sale was made solely to cover taxes from restricted stock units vesting that day, pursuant to a previously adopted Rule 10b5-1 trading plan. After the sale, he directly held 20,079 shares and was reported as indirectly associated with 9,606,408 shares held by SNBL USA, Ltd. and Shin Nippon Biomedical Laboratories, Ltd., for which he disclaims beneficial ownership beyond any pecuniary interest.
Wave Life Sciences, Inc. director Tan Aik Na reported a small open-market sale of 432 shares of common stock on August 11, 2026 at $6.01 per share. According to the disclosure, the shares were sold solely to cover taxes from vesting restricted stock units on the same date, under a previously adopted Rule 10b5-1 Trading Plan. Following this transaction, the director directly holds 24,968 shares of Wave Life Sciences, Inc. common stock.
Wave Life Sciences Ltd. (WVE) director Adrian G. Rawcliffe reported a proposed sale of 12,700 common shares, with an approximate sale date of August 12, 2026.
The notice gives an aggregate market value of $64,071.50 and lists 197,048,175 common shares outstanding. It records March 6, 2026 as the date of plan adoption or instruction, if relying on Rule 10b5-1.